Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/22187| Title: | EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. | Austin Authors: | Horwich, A;Babjuk, M;Bellmunt, J;Bruins, H M;Reijke, T M De;Santis, M De;Gillessen, S;James, N;Maclennan, S;Palou, J;Powles, T;Sengupta, Shomik ;Sherif, A;Smeenk, R J;Smits, A;Stenzl, A;Thalmann, G N;Tombal, B;Turkbey, B;Lauridsen, S Vahr;Valdagni, R;Ribal, M J;Van Der Heijden, A G;Van Poppel, H;Vartolomei, M D;Veskimäe, E;Vilaseca, A;Rivera, F A Vives;Wiegel, T;Wiklund, P;Williams, A;Zigeuner, R;Shariat, S F;Witjes, J A;Kwast, T Van Der;Xylinas, E;Agarwal, N;Arends, T;Bamias, A;Birtle, A;Black, P C;Bochner, B H;Bolla, M;Boormans, J L;Bossi, A;Briganti, A;Brummelhuis, I;Burger, M;Castellano, D;Cathomas, R;Chiti, A;Choudhury, A;Compérat, E;Crabb, S;Culine, S;Bari, B De;Blok, W De;De Visschere, P J L;Decaestecker, K;Dimitropoulos, K;Dominguez-Escrig, J L;Fanti, S;Fonteyne, V;Frydenberg, M;Futterer, J J;Gakis, G;Geavlete, B;Gontero, P;Grubmüller, B;Hafeez, S;Hansel, D E;Hartmann, A;Hayne, D;Henry, A M;Hernandez, V;Herr, H;Herrmann, K;Hoskin, P;Huguet, J;Jereczek-Fossa, B A;Jones, R ;Kamat, A M;Khoo, V;Kiltie, A E;Krege, S;Ladoire, S;Lara, P C;Leliveld, A;Linares-Espinós, E;Løgager, V;Lorch, A;Loriot, Y;Meijer, R;Mir, M Carmen;Moschini, M;Mostafid, H;Müller, A-C;Müller, C R;N'Dow, J;Necchi, A;Neuzillet, Y;Oddens, J R;Oldenburg, J;Osanto, S;Oyen, W J G;Pacheco-Figueiredo, L;Pappot, H;Patel, M I;Pieters, B R;Plass, K;Remzi, M;Retz, M;Richenberg, J;Rink, M;Roghmann, F;Rosenberg, J E;Rouprêt, M;Rouvière, O;Salembier, C;Salminen, A;Sargos, P | Affiliation: | Emeritus Professor, The Institute of Cancer Research, London, UK Depatment of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic Department of Urology, Medical University of Vienna, Vienna, Austria IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain Harvard Medical School, Boston, USA Department of Urology, Radboud University Medical Center, Nijmegen Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands Department of Urology, Medical University of Vienna, Vienna, Austria Department of Urology, Charité University Hospital, Berlin, Germany Division of Cancer Sciences, University of Manchester, Manchester The Christie NHS Foundation Trust, Manchester, UK Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland Department of Urology, Royal Surrey County Hospital, Guildford, UK Department of Radiation Oncology, Eberhard Karls University, Tübingen, Germany Cancer Treatment Centre, Sorlandet Hospital, Kristiansand, Norway Academic Urology Unit, University of Aberdeen, Aberdeen, UK Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK Department of Medical Oncology, Istituto Nazionale Tumori of Milan, Milan, Italy Department of Urology, Hospital Foch, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands Division of Oncology and Haematology, Kantonsspital St Gallen, St Gallen Department of Oncology, Akershus University Hospital, Lørenskog Faculty of Medicine, University of Oslo, Oslo, Norway Department of Clinical Oncology, Leiden University Medical Center, Leiden Department of Biomedical Sciences, Humanitas University, Milan Humanitas Research Hospital, Milan, Italy Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, The Netherlands Department of Urology, Centro Hospitalar São João, Porto Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal Department of Oncology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark University of Bern, Bern, Switzerland Department of Urology, Westmead Hospital, University of Sydney, Sydney, Australia Department of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam EAU Guidelines Office, Arnhem, The Netherlands Department of Urology, Medical University of Vienna, Vienna, Austria Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany Department of Imaging and Nuclear Medicine, Royal Sussex County Hospital, Brighton Brighton and Sussex Medical School, Brighton, UK Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany Department of Medicine, Memorial Sloan Kettering Cancer Center, New York University Hospitals Birmingham NHS Foundation Trust, Birmingham Weill Cornell Medical College, New York, USA Department of Urology, Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, Paris Hospices Civils de Lyon, Service d'Imagerie Urinaire et Vasculaire, Hôpital Edouard Herriot, Lyon Université de Lyon, Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France Department of Radiation Oncology, Europe Hospitals Brussels, Brussels, Belgium Department of Urology, University Hospital of Turku, Turku, Finland Department of Radiotherapy, Institut Bergonié, Bordeaux, France Surgery Eastern Health Clinical School, Monash University, Melbourne, Australia Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands Department of Urology, Radboud University Medical Center, Nijmegen Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany Department of Urology, Inselspital, Bern University Hospital, Berne, Switzerland Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCL, Brussels, Belgium Molecular Imaging Program, National Cancer Institute, Bethesda, USA Department of Urology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Department of Urology, Radboud University Medical Center, Nijmegen Department of Urology, University Hospitals Leuven, Leuven, Belgium Academic Urology Unit, University of Aberdeen, Aberdeen, UK Department of Urology, Medical University of Vienna, Vienna, Austria Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania Department of Urology, Tampere University Hospital, Tampere, Finland Uro-Oncology Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain Clinica HematoOncologica Bonadona Prevenir, Universidad Metropolitana, Clinica Club de Leones, Barranquilla, Colombia Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany Icahn School of Medicine, Mount Sinai Health System, New York City, USA Department of Urology, Karolinska Institutet, Stockholm, Sweden Department of Urology, Auckland City Hospital, Auckland, New Zealand Department of Urology, Medizinische Universität Graz, Graz, Austria Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain Department of Urology, Radboud University Medical Center, Nijmegen The Royal Free NHS Trust, London Barts Cancer Institute, Queen Mary University of London, London, UK Uro-Oncology Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain Depatment of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic Department of Urology, Medical University of Vienna, Vienna, Austria Department of Urology, Weill Cornell Medical College, New York Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique Hôpitaux de Paris, Paris Paris Descartes University, Paris, France Huntsman Cancer Institute, University of Utah (NCI-CCC), Salt Lake City, USA Urology Department, Canisius-Wilhelmina Ziekenhuis Nijmegen, Nijmegen, The Netherlands 2nd Propaedeutic Dept of Internal Medicine, Medical School, National & Kapodistrian University of Athens, Athens, Greece Division of Cancer Sciences, University of Manchester, Manchester Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada Department of Urology, Weill Cornell Medical College, New York Urology Service, Department of Urology, Memorial Sloan Kettering Cancer Center, New York, USA Emeritus Professor of Radiation Oncology, Grenoble - Alpes University, Grenoble, France Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands Department of Radiation Oncology, Gustave Roussy Institute, Villejuif, France Department of Urology, Urological Research Institute, Milan Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy Department of Urology, Radboud University Medical Center, Nijmegen Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany Medical Oncology Department, 12 de Octubre University Hospital (CIBERONC), Madrid, Spain Department Innere Medizin, Abteilung Onkologie und Hämatologie, Kantonsspital Graubünden, Chur, Switzerland Department of Biomedical Sciences, Humanitas University, Milan Humanitas Research Hospital, Milan, Italy Division of Cancer Sciences, University of Manchester, Manchester The Christie NHS Foundation Trust, Manchester, UK Department of Pathology, Tenon Hospital, HUEP, Paris Sorbonne University, Paris, France Cancer Sciences Unit, University of Southampton, Southampton, UK Department of Cancer Medicine, Hôpital Saint Louis, Paris Radiation Oncology Department, Centre Hospitalier Régional Universitaire "Jean Minjoz" of Besançon, INSERM UMR 1098, Besançon, France Radiation Oncology Department, Centre Hospitalier Universitaire Vaudois, Université de Lausanne, Lausanne, Switzerland Department of Urology, University Medical Center Utrecht, Utrecht, The Netherlands Department of Radiology and Nuclear Medicine, Division of Genitourinary Radiology and Mammography, Ghent University Hospital, Ghent Department of Urology, Ghent University Hospital, Ghent, Belgium Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain Department of Nuclear Medicine, Policlinico S Orsola, University of Bologna, Bologna, Italy Department of Radiotherapy Oncology, Ghent University Hospital, Ghent, Belgium Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands Department of Urology and Paediatric Urology, University Hospital of Würzburg, Julius-Maximillians University, Würzburg, Germany Department of Urology, Saint John Emergency Clinical Hospital, Bucharest, Romania Division of Urology, Molinette Hospital, University of Studies of Torino, Torino, Italy Department of Urology, Medical University of Vienna, Vienna, Austria Division of Radiotherapy and Imaging, The Institute of Cancer Research, London Department of Clinical Oncology, The Royal Marsden NHS Foundation Trust, London, UK Department of Urology, University of California, San Diego Pathology, La Jolla, USA Institute of Pathology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Erlangen, Germany Department of Urology, UWA Medical School, University of Western Australia, Perth, Australia Leeds Institute of Medical Research, University of Leeds, Leeds, UK Department of Urology, Hospital Universitario Fundación de Alcorcón, Madrid, Spain Urology Service, Department of Urology, Memorial Sloan Kettering Cancer Center, New York, USA Department of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany Division of Cancer Sciences, University of Manchester, Manchester The Christie NHS Foundation Trust, Manchester, UK Mount Vernon Centre for Cancer Treatment, London, UK Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain Department of Oncology and Hemato-oncology, University of Milan, Milan Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK Department of Urology - Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, USA Division of Radiotherapy and Imaging, The Institute of Cancer Research, London Department of Clinical Oncology, The Royal Marsden NHS Foundation Trust, London, UK Department of Medicine, University of Melbourne, Melbourne Monash University, Melbourne, Australia CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK Department of Urology, Pediatric Urology and Urologic Oncology, Kliniken Essen-Mitte, Essen, Germany Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France Department of Oncology, Hospital Universitario San Roque, Canarias Universidad Fernando Pessoa, Canarias, Spain Department of Urology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands Department of Urology, University Hospital La Paz, Madrid, Spain Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland Département de Médecine Oncologique, Gustave Roussy, INSERM U981, Université Paris-Sud, Université Paris-Saclay, Villejuif, France UMC Utrecht Cancer Center, MS Oncologic Urology, Utrecht, The Netherlands |
Issue Date: | Nov-2019 | Date: | 2019-11-19 | Publication information: | Annals of Oncology : Official Journal of the European Society for Medical Oncology 2019; 30(11): 1697-1727 | Abstract: | Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. Online Delphi survey and consensus conference. The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/22187 | DOI: | 10.1093/annonc/mdz296 | ORCID: | 0000-0003-3357-1216 |
Journal: | Annals of Oncology : Official Journal of the European Society for Medical Oncology | PubMed URL: | 31740927 | Type: | Journal Article | Subjects: | Delphi bladder cancer consensus diagnosis follow-up treatment |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.